Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial

Name: Αlpha¹ Rigor Record — Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial
Item: Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial
Rating: 82
Author: Αlpha¹

Wong GL, Yuen MF, Lin B, Douglas MW, Hu P, Xie Q, Lv F, Tak WY, Leerapun A, Kim DJ, Tangkijvanich P, Lim YS, Dai CY, O'Beirne J, Weltman M, Khemnark S, Piratvisuth T, Manasirisuk W, Chen X, Liu CJ, Heo J, Lee J, Niu J, Kumar R, Kumar R, Zhu C, Cao K, Tian A, Chen X, Zhu Q, Margolis D, Jia J, Hong Z.

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.25★ (Strong), 0 critical, 4 high issues for “Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ReportingData & code availability not met−0.5★
ReportingKey resources partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced2 types

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted and clearly reported phase 2 trial with strong scientific premise, adequate randomization, detailed eligibility criteria, and transparent reporting of ethics, demographics, and limitations. The main weaknesses are reproducibility-related: a vague data-availability statement with no managed-access mechanism, no shared analysis code, threshold-only p-values, and missing manufacturer/source information for the investigational products.

All three independent reviewer runs were synthesized at the checklist level; the main divergences (study design pass vs warn; statistical analysis pass vs warn; data code availability fail vs warn) were resolved by weighing the specific evidence and the scoring rules. The statistics verification component recomputed 0 tests (none met the machine-verifiable criteria), so statistical correctness beyond the reported consistency is unverified. No retracted or non-findable references were flagged; the one reproducibility link checked was live.

9 major claims checked against the paper's own evidence: all adequately supported.

Reporting

Eight Dimensions6 pass · 1 warn · 1 fail

The paper cites prior studies on elebsiran, PEG-IFNα, and BRII-179, acknowledges the lack of a PEG-IFNα control in earlier work, and provides a logical rationale for the combination therapy and the use of BRII-179 for immunological profiling. Limitations of the current study and prior work are discussed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The scientific premise is well-established with citations to prior work, a clear rationale, and discussion of limitations of previous studies.

Evidence

paraphrase[Main text, paragraph 4]

“A prior study evaluating elebsiran in combination with PEG-IFNα reported an HBsAg loss rate of approximately 30% at the end of treatment (EOT) in participants with chronic HBV infection. However, this study lacked a PEG-IFNα monotherapy control, limiting direct comparison.”

paraphrase[Main text, paragraph 5]

“Therefore, we conducted an open-label, phase 2 study (ENSURE, NCT05970289) consisting of two parts... Part I was a randomized study... evaluating the efficacy and safety of elebsiran in combination with PEG-IFNα compared with PEG-IFNα monotherapy.”

direct quote[Discussion, paragraph 6]

“This study has some limitations. Approximately 1.5 years, on average, elapsed between the BRII-179-835-001 study and the ENSURE study, and the impact of this gap in time is unknown.”